The Library
Decreased plasma omentin-1 levels in Type 1 diabetes mellitus
Tools
Tools
Tools
Tan, Bee K., Pua, S., Syed, Farhatullah, Lewandowski, K. C., O'Hare, J. Paul and Randeva, Harpal S. (2008) Decreased plasma omentin-1 levels in Type 1 diabetes mellitus. Diabetic Medicine, Vol.25 (No.10). pp. 1254-1255. doi:10.1111/j.1464-5491.2008.02568.x
Research output not available from this repository, contact author.
Official URL: http://dx.doi.org/10.1111/j.1464-5491.2008.02568.x
Abstract
Context:The novel adipokine, nesfatin-1/NUCB-2, reduces food intake, levels of which are elevated in overweight individuals.
Objectives:The aim of the study was to investigate the mechanisms underlying brain nesfatin-1/NUCB-2 uptake and to determine whether reduced uptake may contribute to nesfatin-1/NUCB-2 resistance.
Design:Cerebrospinal fluid (CSF) and corresponding plasma nesfatin-1/NUCB-2 were measured by ELISA [18 men and 20 women; age, 19–80 yr; body mass index (BMI), 16.2–38.1 kg/m2] and correlated to body adiposity and metabolic parameters.
Results:CSF/plasma nesfatin-1/NUCB-2 ratio was significantly negatively associated with BMI, body weight, fat mass, and CSF glucose. BMI was predictive of CSF/plasma nesfatin-1/NUCB-2 ratio (β = −0.786; P = 0.045). CSF nesfatin-1/NUCB-2 was significantly positively associated with plasma nesfatin-1/NUCB-2 (R = 0.706; P < 0.01). There was a significant linear relation between CSF and plasma nesfatin-1/NUCB-2 in lean (BMI <25 kg/m2; R = 0.744; P = 0.002) and obese (BMI ≥30 kg/m2; R = 0.693; P = 0.026) subjects. Subjects in the highest plasma nesfatin-1/NUCB-2 quintile had lower CSF/plasma nesfatin-1/NUCB-2 ratio [26.5% (26.0–29.5%)] compared to the lowest plasma nesfatin-1/NUCB-2 quintile [38.5% (34.0–42.0%)] (P < 0.01), corresponding BMI [32.4 (31.0–35.0) vs. 23.3 (19.7–23.5) kg/m2; P < 0.01], and fat mass [32.8 (29.5–40.6) vs. 30.7 (8.2–20.1) kg/m2; P < 0.01].
Conclusions:Our observations have important implications with respect to the potential weight-reducing actions of nesfatin-1/NUCB-2 treatment. Future research should seek to clarify whether nesfatin-1/NUCB-2 would be beneficial in the management of obesity.
| Item Type: | Journal Item | ||||
|---|---|---|---|---|---|
| Subjects: | R Medicine > RC Internal medicine | ||||
| Divisions: | Faculty of Medicine > Warwick Medical School | ||||
| Library of Congress Subject Headings (LCSH): | Diabetes, Insulin resistance, Adipose tissues | ||||
| Journal or Publication Title: | Diabetic Medicine | ||||
| Publisher: | Wiley-Blackwell Publishing Ltd. | ||||
| ISSN: | 0742-3071 | ||||
| Official Date: | October 2008 | ||||
| Dates: |
|
||||
| Volume: | Vol.25 | ||||
| Number: | No.10 | ||||
| Number of Pages: | 3 | ||||
| Page Range: | pp. 1254-1255 | ||||
| DOI: | 10.1111/j.1464-5491.2008.02568.x | ||||
| Status: | Peer Reviewed | ||||
| Publication Status: | Published | ||||
| Access rights to Published version: | Restricted or Subscription Access | ||||
| Funder: | General Charities of the City of Coventry |
Data sourced from Thomson Reuters' Web of Knowledge
Request changes or add full text files to a record
Repository staff actions (login required)
 |
View Item |
